10.13
-0.05 (-0.49%)
| Previous Close | 10.18 |
| Open | 10.19 |
| Volume | 693,683 |
| Avg. Volume (3M) | 1,146,939 |
| Market Cap | 780,889,280 |
| Price / Book | 1.92 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -3.07 |
| Total Debt/Equity (MRQ) | 18.32% |
| Current Ratio (MRQ) | 7.95 |
| Operating Cash Flow (TTM) | -192.25 M |
| Levered Free Cash Flow (TTM) | -110.31 M |
| Return on Assets (TTM) | -31.26% |
| Return on Equity (TTM) | -62.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Replimune Group, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.51% |
| % Held by Institutions | 107.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Boxer Capital Management, Llc | 31 Mar 2025 | 1,796,341 |
| 52 Weeks Range | ||
| Median | 22.00 (117.18%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 02 Jun 2025 | 22.00 (117.18%) | Buy | 9.57 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Jun 2025 | Announcement | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 01 Jun 2025 | Announcement | Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting |
| 29 May 2025 | Announcement | Replimune to Present at the 2025 Jefferies Global Healthcare Conference |
| 22 May 2025 | Announcement | Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update |
| 16 May 2025 | Announcement | Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day |
| 09 May 2025 | Announcement | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 11 Apr 2025 | Announcement | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |